{"disease":{"id":"adjunctive-treatment-of-major-depressive-disorder","name":"adjunctive treatment of major depressive disorder"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03968159","title":"Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":298,"lead_sponsor_name":"ACADIA Pharmaceuticals Inc.","has_results":true},{"nct_id":"NCT04000009","title":"Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":235,"lead_sponsor_name":"ACADIA Pharmaceuticals Inc.","has_results":true},{"nct_id":"NCT04103892","title":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":146,"lead_sponsor_name":"Clexio Biosciences Ltd.","has_results":true},{"nct_id":"NCT06340958","title":"A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":99,"lead_sponsor_name":"Clexio Biosciences Ltd.","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}